Slide 1: Exchange filing cover letter for Investor Presentation
13th May, 2025 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Scrip Code: 500087 Bandra (East), Mumbai - 400 051 Scrip C
Slide 2: Investor Presentation Q4FY25
Investor Presentation Q4FY25 13-05-2025 1
Slide 3: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual
Slide 4: Robust Performance across Geographies; Financial Metrics Show continued Improvement
Robust Performance across Geographies; Financial Metrics Show continued Improvement1 Revenue EBITDA PAT 9% 17% 30% Q4FY25 INR 6,730 Cr (YoY) INR 1,538 Cr 150 bps INR 1,222 Cr 292 bps (YoY) (YoY) 14% 28% FY25 INR 27,548 Cr 8% INR 7,128 Cr 139 bps INR 5,273 Cr 301 bps (YoY) (YoY) (YoY) Business Perfor
Slide 5: Financial Performance: Q4FY25
Financial Performance : Q4FY25 Revenues INR 6,730 Cr EBITDA INR 1,538 Cr Revenue1 Break-up Q4FY25 (Consolidated) API, 3% Q4FY25 vs Q4FY24 Others, 1% (INR Cr) Emerging Total Revenue from markets and 6,730 9.2% Operations Europe, 13% One India, EBITDA 1,538 16.8% 39% EBITDA % 22.8% 150 bps One Africa,
Slide 6: Financial Performance: FY25
Financial Performance2 : FY25 Revenues INR 27,548 Cr EBITDA INR 7,128 Cr Revenue1 Break-up FY25 (Consolidated) API, 2% Others, 1% FY 25 (INR Cr) vs FY24 Emerging Markets & Europe, 12% Total Revenue from 27,548 8.2% Operations EBITDA 7,128 14.4% One India, One Africa, 14% 42% EBITDA % 25.9% 139 bps P
Slide 7: Strategic Focus Driving Steady Expansion
Strategic Focus Driving Steady Expansion1 INR Cr Revenue EBITDA 27,548 8,000 24.5% 25.9% 30.0% 25,455 7,000 22,334 22.5% 22.2% 25.0% 21,763 6,000 21.0% 19,160 20.0% 5,000 4,000 15.0% 3,000 10.0% 2,000 5.0% 1,000 4,303 4,578 4,952 6,233 7,128 - 0.0% FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 P
Slide 8: Strong Net-Cash: Assembling Resources to Fuel Growth Investments
Strong Net-Cash : Assembling Resources to Fuel Growth Investments; $ 1 Bn+ Net Cash Position in our Balance Sheet INR Cr Total Debt Total Cash1 10,807 2,014 8,267 6,273 1,756 1,056 4,965 803 3,756 824 559 520 438 247 92 259 232 283 312 346 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Lease Liab
Slide 9: One India: Building a Sustainable Legacy for Enduring Growth
One India1: Building a Sustainable Legacy for Enduring Growth One India Business FY25 Revenue INR 11,615 Cr Q4FY25 Revenue INR 2,622 Cr 3-year CAGR2 10% 3-year CAGR 10% Branded Prescription Trade Generics Consumer Health ❖ Cipla maintained #2 rank in overall Chronic with improved ❖ Successfully impl
Slide 10: India Branded Prescription – Advancing with Strategic Precision
India Branded Prescription1 – Advancing with Strategic Precision Steady uptake in key therapies growth (%) Rank 3.4 1st Largest pharma company by Volume (units) in IPM Respiratory 6.1 5.1 Foracort became the 1st brand to cross INR 900 Cr Anti-infectives 4th 7.2 in the history of IPM 13.6 Urology 18.
Slide 11: Cipla's Strategic Alliances: Accelerating Inorganic Growth
Cipla’s Strategic Alliances: Accelerating Inorganic Growth CLICK TO EDIT MASTER TITLE STYLE Top deals during the year Upcoming innovative launches Exclusive marketing and distribution agreement with US-based MannKind Partnered with Orchid pharma to launch Corporation for Afrezza® in India antibiotic
Slide 12: India Trade Generics: Establishing Deeper Connect with Strong Growth Levers
India Trade Generics : Establishing Deeper Connect with Strong Growth Levers 5,500+ 15,000+ #1 Stockiest Network Pin codes serviced India’s largest trade 400+ 150,000+ generic business Chemist coverage Retail field team (RTF) Big brands bigger 2 Brands with revenue 5 Brands with revenue INR 50 Cr Ke
Slide 13: FY25: Global Consumer Wellness Franchise Creating Market-Leading Brands
FY25: Global Consumer Wellness Franchise Creating Market-Leading Brands One India : Revenue INR ~1,400+ Cr (12M FY25) 2 1 2 2 2 Pain relief Hydration Skin infection Cold & cough Nicotine Replacement INR 240+ Cr INR 210+ Cr INR 160+ Cr INR 110+ Cr INR 100+ Cr South Africa : Revenue ZAR ~1,600+ Mn (12
Slide 14: North America: Experienced Sustained Momentum in Key Differentiated Assets
North America: Experienced Sustained Momentum in Key Differentiated Assets $ Mn 16%+ 906 934 733 594 FY22 FY23 FY24 FY25 Key generic drug approvals during the year Lanreotide Injection - Nilotinib MILESTONE Capsules - 50, 150 Nano Paclitaxel - 100 MILESTONE 120mg (ANDA) and 200 mg (NDA) mg/vial (AND
Slide 15: North America: Advancing Growth through a Strategic Asset Pipeline
North America: Advancing Growth through a Strategic Asset Pipeline CLICK TO EDIT MASTER TITLE STYLE Pipeline progress Respiratory • 6 assets filed (launches expected in line with the review process) Pipeline • 4 assets to be filed over next 12-18 months Peptides & • 9 assets filed (Some of these lau
Slide 16: Upholding Quality and Compliance Across Manufacturing Facilities
Upholding CLICK Quality TO EDITand Compliance MASTER Across Manufacturing Facilities TITLE STYLE Jun-24* Jul-24 * Oct-24 * Feb-25 * Apr-25 * Patalganga, Kurkumbh, Virgonagar, Medispray, Verna, Goa Maharashtra Maharashtra Bengaluru Goa 5 Manufacturing facilities were audited by the USFDA in FY25 All
Slide 17: ANDA & NDA Portfolio & Pipeline (As on 31st March 2025)
ANDA & NDA Portfolio & Pipeline (As on 31st March 2025) 9 65 9 2 16 92 6 2 2 20 49 12 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs Cipla Ltd PEPFAR 1 Invagen Partnered ANDAs/NDAs 175 36 73 284 Approved Tentatively Under Approval Total ANDAs & NDAs Approved ANDA
Slide 18: One Africa: Continued Progress on Scaling-up Journey
One Africa1 : Continued Progress on Scaling-up Journey $ Mn $ Mn Q4FY25 FY25 63 18 42 9 76 10 14 35 81 16 17 52 68 68 241 266 Q4FY24 Q4FY25 FY24 FY25 SA Private SA Tender North Africa Others (SSA & CGA) SA Private SA Tender North Africa Others (SSA & CGA) Market Segment2 Rank Share Cipla Growth Mark
Slide 19: Emerging Markets & Europe: Building Bolder Presence across Key Markets
Emerging Markets & Europe: Building Bolder Presence across Key Markets & Augmenting Core Capabilities Revenue $ Mn 15% 390 342 346 338 338 FY21 FY22 FY23 FY24 FY25 • Driving operational excellence by demand/Supply & product issue resolution • Commercial excellence in DTM markets through Sales Force
Slide 20: Progressing on 2025 Environmental, Social & Governance Goals
Progressing on 2025 Environmental, Social & Governance Goals Progress on ESG Goals Sustainability ratings Achieved water neutrality in FY 25 against the target timeline of Dec 25. (Independent assurance underway) 50% of water recycled as percentage of water withdrawal CDP Climate : B- (2023) B (2024
Slide 21: Profit and Loss Statement Summary (Reported)
Profit and Loss Statement Summary (Reported) INR Cr Particulars Q4 FY25 FY25 Revenue from sale of products 6,598 27,145 Other operating income 132 402 Income from operations 6,730 27,548 Material cost 2,189 8,929 Employee benefits expense 1,233 4,833 Other expenses 1,770 6,658 Total expenses 5,192 2
Slide 22: Balance Sheet Summary (Reported)
Balance Sheet Summary (Reported) INR Cr Particulars Mar-25 Mar-24 Net Tangible Assets 6,586 6,047 Goodwill & Intangibles 4,986 4,713 Investments 640 642 Other non-current assets 576 406 Advance tax assets (net) 411 442 Deferred tax assets (net) 591 403 Inventories 5,642 5,238 Cash and Cash Equivalen
Slide 23: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 Diksha Maheshwari Investor.Relations@cipla.com For more information, please visit www.cipla.com 22